A股異動丨中國平安漲近3% 股價創近8個月新高 較年內低點反彈超26%
中國平安(601318.SH)午後進一步拉昇,一度漲2.85%至57.39元,股價創去年11月11日以來近8個月新高。該股曾於今年4月7日盤中創年內新低45.4元,迄今不到3個月已反彈超26%,跑贏大盤表現(同期滬指漲約15%)。花旗發研報指,看到多重催化劑將加速共同基金和保險公司對股市的投資,並推動家庭資產向股票重新配置,特別是大盤ETF及高收益率股票,利好指數權重高且高股息的中國金融機構。該行指,保險公司也是共同基金改革的主要受益者,結合強勁的新業務增長、投資回報提升、監管順風及低估值,偏好中國平安。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.